Trial Profile
A Phase I, Open Label Study of MBP-426 Given by Intravenous Infusion in Patients with Advanced or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Dec 2014
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Mebiopharm
- 22 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Sep 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 23 Feb 2007 New trial record.